Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: Results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies

Clinical Drug Investigation

Volumn 29, Issue 1, 2009, Pages 35-50

  Vakily, Majid ^a   Lee, Ronald D ^a   Wu, Jingtao ^a   Gunawardhana, Lhanoo ^a   Mulford, Darcy ^a  

^a TAKEDA PHARMACEUTICALS   (United States)

Author keywords

Cytochrome P450; Dexlansoprazole, drug interactions; Dexlansoprazole, pharmacokinetics; Diazepam, pharmacokinetics; Drug interactions; Phenytoin, pharmacokinetics; Research and development; Theophylline, pharmacokinetics; Warfarin, pharmacodynamics

Indexed keywords

AMINOPHYLLINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A; DEXLANSOPRAZOLE; DIAZEPAM; LANSOPRAZOLE; PHENYTOIN; PROTON PUMP INHIBITOR; TAK 390; TAK 390MR; UNCLASSIFIED DRUG; WARFARIN;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DELAYED RELEASE FORMULATION; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG RELEASE; DRUG TOLERABILITY; ENANTIOMER; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MODIFIED RELEASE FORMULATION; NORMAL HUMAN; PHARMACEUTICAL ENGINEERING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTICOAGULANTS; ANTICONVULSANTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DIAZEPAM; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENYTOIN; PROTON PUMP INHIBITORS; THEOPHYLLINE; WARFARIN; YOUNG ADULT;

EID: 57449085402     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/0044011-200929010-00004     Document Type: Article

References (40)

1. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005 Jan; 100 (1): 190-200
2. Gerson LB, Triadafilopoulos G. Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur J Gastroenterol Hepatol 2001 May; 13 (5): 611-6
3. Blume H, Donath F, Warnke A, et al. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf 2006; 29 (9): 769-84
4. Reilly JP. Safety profile of the proton-pump inhibitors. Am J Health Syst Pharm 1999 Dec 1; 56 (23 Suppl. 4): S11-7
5. Li XQ, Andersson TB, Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004 Aug; 32 (8): 821-7
6. Simon W. Pantoprazole: which cytochrome P450 isoenzymes are involved in its biotransformation? [abstract]. Gut 1995; 37: A1177
7. Humphries TJ, Merritt GJ. Drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther 1999 Aug; 13 Suppl. 3: 18-26
8. Caraco Y, Tateishi T, Wood AJ. Interethnic difference in omeprazole's inhibition of diazepam metabolism. Clin Pharmacol Ther 1995 Jul; 58 (1): 62-72
9. Andersson T, Cederberg C, Edvardsson G, et al. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther 1990 Jan; 47 (1): 79-85
10. Gugler R, Jensen JC. Omeprazole inhibits oxidative drug metabolism: studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 1985 Dec; 89 (6): 1235-41
11. Nexium® (esomeprazole magnesium). Full prescribing information. Wilmington (DE): AstraZeneca LP, 2007
12. Saltiel E, Fask A. Prevalence of potential proton-pump inhibitor drug interactions: a retrospective review of prescriptions in community pharmacies. Clin Ther 1999 Oct; 21 (10): 1812-9
13. McCarthy DM, McLaughlin TP, Griffis DL, et al. Impact of cotherapy with some proton pump inhibitors on medical claims among HMO patients already using other common drugs also cleared by cytochrome P450. Am J Ther 2003 Sep-Oct; 10 (5): 330-40
14. Ramirez FC. Diagnosis and treatment of gastroesophageal reflux disease in the elderly. Cleve Clin J Med 2000 Oct; 67 (10): 755-66
15. van der Meer FJ, Rosendaal FR, Vandenbroucke JP, et al. Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch Intern Med 1993 Jul 12; 153 (13): 1557-62
16. Prevacid® (lansoprazole). Full prescribing information. Lake Forest (IL): TAP Pharmaceutical Products, Inc., 2007
17. Aciphex® (rabeprazole sodium). Full prescribing information. Tokyo: Eisai Co. Ltd, 2007
18. Protonix® (pantoprazole sodium). Full prescribing information. Philadelphia (PA): Wyeth Pharmaceuticals, Inc., 2007
19. Prilosec® (omeprazole). Full prescribing information. Wilmington (DE): AstraZeneca LP, 2007
20. Zegerid® (omeprazole bicarbonate). Full prescribing information. San Diego (CA): Santarus, Inc., 2006
21. Zhang W, Wu J, Atkinson S. Pharmacokinetics, pharmacodynamics, and safety evaluation of a single and multiple 60 mg, 90 mg, and 120 mg oral doses of modified-release TAK-390 (TAK-390MR) and 30 mg oral doses of lansoprazole in healthy subjects [abstract]. Gastroenterology 2007; 132 Suppl. 52: A87
22. Liu KH, Kim MJ, Jung WM, et al. Lansoprazole enantiomer activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner. Drug Metab Dispos 2005 Feb; 33 (2): 209-13
23. Curi-Pedrosa R, Daujat M, Pichard L, et al. Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J Pharmacol Exp Ther 1994 Apr; 269 (1): 384-92
24. Granneman GR, Karol MD, Locke CS, et al. Pharmacokinetic interaction between lansoprazole and theophylline. Ther Drug Monit 1995 Oct; 17 (5): 460-4
25. Inomata S, Nagashima A, Itagaki F, et al. CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. Clin Pharmacol Ther 2005 Dec; 78 (6): 647-55
26. Andersson T, Rohss K, Bredberg E, et al. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther 2001 Oct; 15 (10): 1563-9
27. Lee SY, Lee ST, Kim JW. Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting. J Biochem Mol Biol 2007 May 31; 40 (3): 448-52
28. Horsmans Y, Van den Berge V, Bouckaert A, et al. Phenytoin hydroxylation in a healthy Caucasian population: bimodal distribution of hydroxyphenytoin urinary excretion. Pharmacol Toxicol 1997; 8 (6): 276-9
29. Sarkar MA, Hunt C, Guzelian PS, et al. Characterization of human liver cytochromes P-450 involved in theophylline metabolism. Drug Metab Dispos 1992 Jan-Feb; 20 (1): 31-7
30. Priskorn M, Sidhu JS, Larsen F, et al. Investigation of multiple dose citalopram on the pharmacokinetics and pharmaco-dynamics of racemic warfarin. Br J Clin Pharmacol 1997; 44: 199-202
31. Dingemanse J, Meyerhoff C, Schadrack J. Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin. Br J Clin Pharmacol 2002 May; 53 (5): 485-91
32. Reynolds KK, Valdes R, Hartung BR, et al. Individualizing warfarin therapy. Personalized Med 2007; 4 (1): 11-31
33. Lefebvre RA, Flouvat B, Karolac-Tamisier S, et al. Influence of lansoprazole treatment on diazepam plasma concentration. Clin Pharmacol Ther 1992; 52 (5): 458-63
34. Prichard PJ, Walt RP, Kitchingman GK, et al. Oral phenytoin pharmacokinetics during omeprazole therapy. Br J Clin Pharmacol 1987; 24 (4): 543-5
35. Dilger K, Zheng Z, Klotz U. Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline. Br J Clin Pharmacol 1999; 48 (3): 438-44
36. Study No. (C03-057). Lake Forest (IL): Takeda Global Research & Development Center, Inc., 2004. (Data on file)
37. Juurlink DN, Mamdani M, Kopp A, et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003 Apr 2; 289 (13): 1652-8
38. Andersson T, Hassan-Alin M, Hasselgren G, et al. Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001; 40 (7): 523-37
39. Sutfin T, Balmer K, Bostrom H, et al. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 1989; 11 (2): 176-84
40. Unge P, Svedberg LE, Nordgren A, et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmacol 1992 Dec; 34 (6): 509-12